Results 301 to 310 of about 289,605 (341)

Exosome encapsulated albumin nanoparticles target delivery of DBET6 as a treatment for triple-negative breast cancer. [PDF]

PLoS One
Yu H, Zhao J, Wu D, Yuan H.
europepmc   +1 more source

Triple-negative breast cancer. [PDF]

Wiener Medizinische Wochenschrift, 2010
Recent advances in biological characterization of breast cancer have eventually increased our understanding of underlying tumour biology. While for endocrine responsive and Her2-positive disease different molecular targeted therapies are available, up to now no specific targeted approach for triple-negative breast cancer has been developed.
W. Foulkes, I. Smith, J. Reis-Filho
semanticscholar   +13 more sources

Some of the next articles are maybe not open access.

Related searches:

Triple-negative breast cancer.

Current Opinion in Oncology, 2008
Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor.
Debra L Winkeljohn
semanticscholar   +6 more sources

Metastatic Triple-negative Breast Cancer

Clinical Oncology, 2011
The triple-negative class (oestrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) comprises about 15% of breast cancer. It is associated with a poor prognosis compared with tumours that are positive for hormone receptors or HER2.
E A, Rakha, S, Chan
openaire   +2 more sources

Triple-Negative Breast Cancer

DeckerMed CGSO Case-Based Reviews, 2019
Triple-negative breast cancer (TNBC) represents approximately 15% of breast cancers and is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2). The annual incidence of TNBC is estimated to be approximately 40,000, with 20,000 diagnosed with metastatic ...
Ritika Vankina, Yuan Yuan
openaire   +2 more sources

Advanced Triple-Negative Breast Cancer

Seminars in Oncology Nursing
Our focus within this review is to summarize key advances and new therapeutic approaches within advanced triple-negative breast cancer. In addition, we highlight the importance of multidisciplinary management, discussing key issues for patients and importance of the supportive role that specialist nurses provide.Peer-reviewed literature, clinical ...
Patel, G, Prince, A, Harries, M
openaire   +3 more sources

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

New England Journal of Medicine
BACKGROUND In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing ...
P. Schmid, J. Cortés, R. Dent, H. McArthur, L. Pusztai, S. Kümmel, C. Denkert, Y. Park, R. Hui, N. Harbeck, M. Takahashi, Seock-Ah Im, M. Untch, P. Fasching, M. Mouret-Reynier, T. Foukakis, M. Ferreira, F. Cardoso, Xuan Zhou, V. Karantza, K. Tryfonidis, G. Aktan, J. O’Shaughnessy   +22 more
semanticscholar   +1 more source

Live Macrophage-Delivered Doxorubicin-Loaded Liposomes Effectively Treat Triple-Negative Breast Cancer.

ACS Nano, 2022
Triple-negative breast cancer is often aggressive and resistant to various cancer therapies, especially corresponding targeted drugs. It is shown that targeted delivery of chemotherapeutic drugs to tumor sites could enhance treatment outcome against ...
Lan Yang, Yongshun Zhang, Yu Zhang, Yani Xu, Yuai Li, Zhiqiang Xie, Hairui Wang, Yunzhu Lin, Qing Lin, T. Gong, Xun Sun, Zhirong Zhang, Ling Zhang   +12 more
semanticscholar   +1 more source

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

Journal of the American Medical Association (JAMA)
Importance The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with adjuvant or neoadjuvant ...
R. Leon-Ferre, S. Jonas, R. Salgado, S. Loi, V. D. de Jong, Jodi M. Carter, Torsten O. Nielsen, Samuel Leung, N. Riaz, Stephen K. L. Chia, Gerome Jules-Clement, G. Curigliano, C. Criscitiello, Vincent Cockenpot, M. Lambertini, Vera J Suman, B. Linderholm, John W. M. Martens, C. V. van Deurzen, A. M. Timmermans, T. Shimoi, S. Yazaki, Masayuki Yoshida, Sung-Bae Kim, Hee Jin Lee, M. Dieci, Guillaume Bataillon, A. Vincent‐Salomon, Fabrice André, M. Kok, Sabine C. Linn, M. Goetz, S. Michiels   +32 more
semanticscholar   +1 more source

Epidemiology of triple negative breast cancers [PDF]

Breast Disease, 2011
Triple negative (TN) breast cancers fail to express the three most common breast cancer receptors; i.e., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Accumulating data demonstrate that epidemiological risk factor profiles also vary between TN (ER-PR-HER2-) and other breast cancers, especially ...
Gretchen L, Gierach, Aileen, Burke, William F, Anderson   +2 more
openaire   +2 more sources